Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CDK2AP1 | O14519 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16801898 | 1.00 | MAPK1 (0.47) | MAPK1OPRK1CDK2AP1CHEK1SLC6A1 | |
| SCHEMBL28231320 | 0.89 | EPHX1 (0.45) | MAPK1OPRK1LMNAEPHX1CA1 | |
| SCHEMBL28231346 | 0.89 | EPHX1 (0.45) | MAPK1OPRK1LMNAEPHX1CA1 | |
| Hydrochloric Acid SCHEMBL28827123 | 0.87 | EPHX1 (0.44) | MAPK1OPRK1LMNAEPHX1CA1 | |
| Hydrochloric Acid SCHEMBL28060562 | 0.87 | EPHX1 (0.44) | MAPK1OPRK1LMNAEPHX1CA1 | |
| SCHEMBL24790610 | 0.86 | EPHX1 (0.55) | EPHX1PKM | |
| SCHEMBL18505997 | 0.81 | LMNA (0.39) | LMNAKMT2AEPHX1CHRNB2CHRNB4 | |
| SCHEMBL1321300 | 0.79 | MAPK1 (0.50) | MAPK1OPRK1CDK2AP1CHEK1SLC6A1 | |
| SCHEMBL1006531 | 0.79 | MAPK1 (0.50) | MAPK1OPRK1CDK2AP1CHEK1SLC6A1 | |
| SCHEMBL11949315 | 0.79 | MAPK1 (0.50) | MAPK1OPRK1CDK2AP1CHEK1SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871772-B1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8003664-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7786136-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1831211-B1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1807422-B1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE INC (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1807423-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7534889-B2 | For reduced motility of gastrointestinal tract; irritable bowel syndrome (IBS), chronic constipation, dyspepsia, reflux disease; 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid ((1S,3R,5R)-8-{3-[(2-ethylsulfanylethyl)methanesulfonylamino]-2-hydroxypropyl}-8-aza-bicyclo[3.2.1]oct-3-yl)amide | THERAVANCE, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7498442-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7446114-B2 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7396933-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080132491-A1 | Indazole-carboxamide compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-05 | — | — | US | disclosed |
| EP-1831211-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | Theravance, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1807422-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | Theravance, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006069125-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006052640-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | MAPK1 2623/4885OPRK1 67/4885CDK2AP1 3889/4885 |
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | HTR4, HTR5A, HTR3B | MAPK1 3337/4885OPRK1 98/4885CDK2AP1 3466/4885 |
| US-20080132491-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | MAPK1 3337/4885OPRK1 98/4885CDK2AP1 3466/4885 |
| US-20060135764-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | MAPK1 3337/4885OPRK1 98/4885CDK2AP1 3466/4885 |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | GIPR, GPR4, GPR119 | MAPK1 1743/4885OPRK1 83/4885CDK2AP1 2810/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | MAPK1 3303/4885OPRK1 61/4885CDK2AP1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.